Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ORGANIZATION
ORGANIZATION
- Asian Pharma Groups Adopt Position Paper to Push E-Labeling
April 20, 2023
- Pharma CEOs Call for Japan’s Leadership to Tackle Global Health Issues at G7 Summit
April 17, 2023
- Japan, US, EU Trade Groups Push Price Maintenance during Patent Period: Joint Statement
April 17, 2023
- European Pharma CEOs Prod Japan to Rethink Drug Pricing System: Forum
April 13, 2023
- Scrap Numerical Target for Generic Use: Gx/Biosimilar Association to Govt
April 11, 2023
- Generic Use Rate Hits Record 81.2% in October-December: JGA
April 7, 2023
- JCHO Bars 6 Wholesalers from Drug Procurement Bids in Kyushu
March 30, 2023
- JOHAS Follows Suit to Suspend 6 Wholesalers from Future Bids
March 29, 2023
- Six Wholesalers Barred from NHO Bids after FTC Confirms Bid-Rigging
March 28, 2023
- Hight Time to Hold Fundamental Debate on Drug Price Revisions: FPMAJ Director General
March 24, 2023
- Japan Umbrella Trade Organ to Beef Up Functions for Lobbying Activity
March 24, 2023
- Over 20% of All Generics under Restricted Shipments: FPMAJ
March 14, 2023
- PhRMA Unveils Proposal for FY2024 Reform, Says This Year Is “Turning Point” to Improve Access
March 10, 2023
- Labor Unions Prod MHLW to Renew Efforts to Improve Compliance with Drug Distribution Guidelines
March 3, 2023
- OB/GYN Group Urges MHLW to Facilitate Access to Oral Abortion Drug
February 24, 2023
- Policy Veterans’ Group Floats Proposal to Prevent Unprofitability to Stabilize Drug Supply
February 21, 2023
- JPMA Chief Calls for Prompt Price Cuts for LLPs, Generic Industry Consolidation
February 17, 2023
- Japan Citizen’s Group Objects Pfizer’s Partnership with Tokyo Govt
February 1, 2023
- PhRMA Poised to Issue 2024 Reform Proposal in Next Few Months: New Japan Chief
January 25, 2023
- Kenporen Director Calls on Pharma Industry, MHLW to Share More Data toward FY2024 Reform
January 20, 2023
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…